aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Taysha Gene Therapies is dedicated to eradicating severe and life-threatening monogenic CNS diseases through the development of curative medicines. The company focuses on rapidly translating treatments from bench to bedside, aiming to provide effective solutions for conditions like Rett syndrome. Their innovative approach targets the root causes of these genetic disorders, offering hope to patients and families affected by these debilitating diseases.
Taysha Gene Therapies has achieved significant milestones, including positive clinical data from ongoing trials and receiving the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for their TSHA- treatment in Rett syndrome. These accomplishments underscore their commitment to advancing gene therapy and improving patient outcomes.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Gene Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Taysha Gene Therapies founded?
Taysha Gene Therapies was founded in 2020.
Where is Taysha Gene Therapies's headquarters located?
Taysha Gene Therapies's headquarters is located in Dallas, US.
When was Taysha Gene Therapies's last funding round?
Taysha Gene Therapies's most recent funding round was for $40M (USD) in December 2023.
How many employees does Taysha Gene Therapies have?
Taysha Gene Therapies has 81 employees as of Feb 6, 2024.
How much has Taysha Gene Therapies raised to-date?
As of July 05, 2023, Taysha Gene Therapies has raised a total of $468M (USD) since Dec 19, 2023.
Add Comparison
Total Raised to Date
$468M
USD
Last Update Dec 19, 2023
Last Deal Details
$40M
USD
Dec 19, 2023
Post Ipo Debt
Total Employees Over Time
81
As of Feb 2024
Taysha Gene Therapies Address
Dallas,
75203
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts